Pharming Group N.V.
Business
Pharming Group N.V. is a global biotechnology company that develops and commercializes innovative therapies for rare and ultra-rare diseases with significant unmet need, focusing on immunological and genetic conditions. The company markets two approved therapies: RUCONEST® (recombinant C1 esterase inhibitor for hereditary angioedema) and Joenja® (leniolisib, a PI3Kδ inhibitor for activated PI3Kδ syndrome). The clinical pipeline includes leniolisib for broader primary immunodeficiencies with immune dysregulation and napazimone (KL1333) for mitochondrial disease. Pharming operates through its U.S. commercial platform and is expanding global access in Europe, Japan, and other key markets.
Summary from 20-F filed 2026-04-02
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $2.54M |
| Total assets | $499.96M |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Pharming Group N.V.'s CIK number?
Pharming Group N.V.'s SEC CIK number is 0001828316 (1828316). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Pharming Group N.V.'s SEC filings?
All of Pharming Group N.V.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.